Over the last three decades, pancreatic cystic neoplasms (PCNs) are being appreciated and recognized with increasing frequency, primarily as a result of increased awareness of these neoplasms and their natural history and the widespread availability and extensive use of ever improving modalities of cross-sectional imaging [1]. Commonly, PCNs are diagnosed incidentally during investigation for often unrelated and nonspecific abdominal complaints using state-of-the art abdominal imaging. The use of the term PCN encompasses a histologically heterogenous group of neoplasms with a wide spectrum of biologic behavior, ranging from completely benign to potentially malignant, to carcinoma in situ, to frankly invasive and malignant [2]. In 1978, Compagno and Oertel were the first to recognize the crucial distinction between the serous and the mucinous cystic neoplasms of the pancreas by explaining the importance of identifying the mucinous neoplasms because of their overt or latent malignant potential [3, 4]. Since then, the interest in PCNs increased markedly, especially so with the recognition of the importance and prevalence of intraductal papillary mucinous neoplasms (IPMNs).